Literature DB >> 23396837

Sugammadex rescue following prolonged rocuronium neuromuscular blockade with 'recurarisation' in a patient with severe renal failure.

Steven Lobaz1, Mario Sammut, Anand Damodaran.   

Abstract

We describe our experience of a 71-year-old patient with severe renal failure, who exhibited an unusually prolonged rocuronium-induced neuromuscular blockade (>4 h) and apparent recurarisation, following emergency rapid sequence induction (RSI). At the end of operation, 45 min post induction, train-of-four (TOF) testing had been 4/4 prior to wake up. No respiratory effort was seen 150 min postinduction, despite further neostigmine/glycopyrrolate and repeat TOF 4/4. The patient was resedated and transferred to the intensive care unit (ICU). At 180 min postinduction, fade was evident on TOF, suggestive of rocuronium reblockade. At 285 min, the patient was extubated safely following sugammadex administration and discharged uneventfully from the ICU. An important lesson to recognise is the potential for extremely prolonged neuromuscular blockade following rocuronium in patients with severe renal failure, particularly when using the higher doses (1.2 mg/kg) required for RSI, and that TOF in such cases may not be reliable in detecting residual blockade.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396837      PMCID: PMC3604464          DOI: 10.1136/bcr-2012-007603

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.

Authors:  Bertrand Debaene; Benoît Plaud; Marie-Pierre Dilly; François Donati
Journal:  Anesthesiology       Date:  2003-05       Impact factor: 7.892

2.  Less is not always more: sugammadex and the risk of under-dosing.

Authors:  Thomas Fuchs-Buder
Journal:  Eur J Anaesthesiol       Date:  2010-10       Impact factor: 4.330

3.  Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.

Authors:  L M Staals; M M J Snoeck; J J Driessen; H W van Hamersvelt; E A Flockton; M W van den Heuvel; J M Hunter
Journal:  Br J Anaesth       Date:  2010-01       Impact factor: 9.166

4.  [Sugammadex and renal failure: a case report].

Authors:  M Briere; C Boisson; P Cuvillon; B Debaene; J Ripart
Journal:  Ann Fr Anesth Reanim       Date:  2011-06-29

5.  The use of rocuronium (ORG 9426) in patients with chronic renal failure.

Authors:  K S Khuenl-Brady; A Pomaroli; F Pühringer; G Mitterschiffthaler; J Koller
Journal:  Anaesthesia       Date:  1993-10       Impact factor: 6.955

6.  Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients.

Authors:  T Suzuki; O Kitajima; K Ueda; Y Kondo; J Kato; S Ogawa
Journal:  Br J Anaesth       Date:  2011-04-29       Impact factor: 9.166

7.  Extremely prolonged neuromuscular blockade after rocuronium: a case report.

Authors:  A C Morales Martín; L M Vaquero Roncero; C Muriel Villoria
Journal:  Acta Anaesthesiol Scand       Date:  2009-04-27       Impact factor: 2.105

8.  The neuromuscular effects of 0.6 mg kg(-1) rocuronium in elderly and young adults with or without renal failure.

Authors:  S Kocabas; D Yedicocuklu; F Z Askar
Journal:  Eur J Anaesthesiol       Date:  2008-06-09       Impact factor: 4.330

9.  Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.

Authors:  R A Cooper; V R Maddineni; R K Mirakhur; J M Wierda; M Brady; K T Fitzpatrick
Journal:  Br J Anaesth       Date:  1993-08       Impact factor: 9.166

10.  Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.

Authors:  L M Staals; M M J Snoeck; J J Driessen; E A Flockton; M Heeringa; J M Hunter
Journal:  Br J Anaesth       Date:  2008-07-23       Impact factor: 9.166

View more
  3 in total

1.  Sugammadex use in patients with end-stage renal disease: a historical cohort study.

Authors:  Stephania Paredes; Steven B Porter; Ivan E Porter; J Ross Renew
Journal:  Can J Anaesth       Date:  2020-09-18       Impact factor: 5.063

2.  Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.

Authors:  Marie T Aouad; Waseem S Alfahel; Roland N Kaddoum; Sahar M Siddik-Sayyid
Journal:  BMC Anesthesiol       Date:  2017-04-11       Impact factor: 2.217

Review 3.  Advantages and pitfalls of clinical application of sugammadex.

Authors:  Hyung Young Lee; Ki Tae Jung
Journal:  Anesth Pain Med (Seoul)       Date:  2020-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.